Oncology Corporate Profile
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage biotechnology company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively known as the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|ETBX-011||immunotherapy||Head & Neck cancer||Preclinical|
View additional information on product candidates here »